Sulopenem is an oral penem antibiotic primarily developed for the treatment of multidrug-resistant bacterial infections, especially those caused by extended-spectrum beta-lactamase (ESBL)-producing Gram-negative organisms. It shows potent activity against a broad range of pathogens, including Escherichia coli, Klebsiella pneumoniae, and Enterobacter species, making it a valuable option for complicated urinary tract infections (cUTIs) and other serious community-acquired infections.

One of its key advantages is oral bioavailability, which allows for effective outpatient treatment of infections that would otherwise require intravenous antibiotics. This supports early discharge from hospitals and reduces healthcare costs. Sulopenem is also being explored for use in treating infections in patients with limited treatment options due to resistance patterns.

It has shown promise in addressing infections associated with sexually transmitted diseases, such as those caused by resistant strains of Neisseria gonorrhoeae. Its development addresses the growing need for new antibiotics that can overcome common resistance mechanisms like beta-lactamase degradation, especially in ambulatory care settings.